Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.80 and traded as low as $2.44. Minerva Neurosciences shares last traded at $2.46, with a volume of 42,326 shares traded.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on NERV shares. StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Friday. They set a “sell” rating on the stock. HC Wainwright dropped their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.
View Our Latest Analysis on NERV
Minerva Neurosciences Stock Up 0.4 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts forecast that Minerva Neurosciences, Inc. will post -2.26 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The How and Why of Investing in Gold Stocks
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Dividend Capture Strategy: What You Need to Know
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.